All In Biotech

Drug Trial Radar · NCT06333860

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 393 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

393

Actual

Start

May 10, 2024

Primary completion

Mar 19, 2026

Study completion Mar 19, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Moderate Plaque Psoriasis

Interventions

  • RisankizumabDrug

    Solution for Subcutaneous (SC) injection

  • DeucravacitinibDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90)Time frame: At Week 16
  2. Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) with at least 2-grade improvement from BaselineTime frame: Baseline, Week 16
  3. Period B: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) in the Intent to Treat Population for non-responders in Period B (ITT_B_NR).Time frame: At Week 52
  4. Number of Participants Experiencing Adverse Events (AEs)Time frame: Baseline up to 73 Weeks

Locations

88 sites in 12 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center /ID# 263011

    Birmingham, Alabama

  • Advanced Research Associates - Glendale /ID# 263621

    Glendale, Arizona

  • Clear Dermatology & Aesthetics Center /ID# 263626

    Scottsdale, Arizona

  • Dermatology Trial Associates /ID# 264480

    Bryant, Arkansas

  • First OC Dermatology /ID# 263003

    Fountain Valley, California

  • Integrative Skin Science and Research /ID# 264504

    Sacramento, California

  • Physioseq, LLC /ID# 265035

    Sacramento, California

  • Medderm Associates Dermatology /ID# 263858

    San Diego, California

  • Southern California Dermatology /ID# 263021

    Santa Ana, California

  • Clearlyderm Dermatology - West Boca /ID# 264963

    Boca Raton, Florida

  • Driven Research /ID# 263002

    Coral Gables, Florida

  • Skin Care Research - Hollywood /ID# 263877

    Hollywood, Florida

  • International Dermatology Research /ID# 264911

    Miami, Florida

  • Lenus Research and Medical Group /ID# 263886

    Miami, Florida

  • Wellness Clinical Research - Miami Lakes /ID# 263887

    Miami Lakes, Florida

  • Skin Care Research - Tampa /ID# 263880

    Tampa, Florida

  • Advanced Clinical Research Institute /ID# 263878

    Tampa, Florida

  • University Dermatology and Vein Clinic, LLC /ID# 263028

    Chicago, Illinois

  • Arlington Dermatology /ID# 263001

    Rolling Meadows, Illinois

  • Dawes Fretzin, LLC /ID# 264578

    Indianapolis, Indiana

  • MetroBoston Clinical Partners /ID# 263860

    Boston, Massachusetts

  • University of Michigan Health System - Ann Arbor /ID# 265233

    Ann Arbor, Michigan

  • Clinical Research Institute of Michigan - Clinton Township Office /ID# 264968

    Clinton Township, Michigan

  • Dermatology and Skin Center of Lees Summit /ID# 263560

    Lee's Summit, Missouri

  • Physician Research Collaboration, LLC /ID# 263568

    Lincoln, Nebraska

  • Skin Cancer and Dermatology Institute - Reno /ID# 263697

    Reno, Nevada

  • StracSkin, PLLC /ID# 263024

    Portsmouth, New Hampshire

  • Oregon Dermatology & Research Center /ID# 263674

    Portland, Oregon

  • Clinical Partners /ID# 263862

    Johnston, Rhode Island

  • Health Concepts /ID# 263016

    Rapid City, South Dakota

  • Arlington Research Center, Inc /ID# 263908

    Arlington, Texas

  • Bellaire Dermatology Associates /ID# 263897

    Bellaire, Texas

  • U.S. Dermatology Partners - Cedar Park /ID# 263906

    Cedar Park, Texas

  • Dermatology Treatment and Research Center /ID# 267071

    Dallas, Texas

  • Texas Dermatology Research Center /ID# 264487

    Plano, Texas

  • Dermatology Clinical Research Center of San Antonio /ID# 263869

    San Antonio, Texas

  • Center for Clinical Studies - Clear Lake /ID# 263009

    Webster, Texas

  • Center for Clinical Studies - Clear Lake /ID# 263917

    Webster, Texas

  • Premier Clinical Research /ID# 263679

    Spokane, Washington

  • Paratus Clinical Research Woden /ID# 263120

    Phillip, Australian Capital Territory, Australia

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.